Twist Bioscience Takes In $81M In Equity, Debt Funding
San Francisco-based Twist Bioscience, a developer of DNA synthesis tools, has raised $81M in total, split between a $61M Series D financing and $20M in debt. According to the company, the Series D funding came from ARCH Overage Fund, Merieux Developpement, Cormorant Asset Management LLC, Fidelity Management and Research Company and Foresite Capital Management LLC, along with ARCH Venture Partners, WuXi Corporate Venture Fund, Illumina, Inc., Nick and Joby Pritzker (via Tao Invest), Paladin Capital Group, Yuri Milner, Boris Nikolic, along with others. The company says it has now raised $133M in equity and $20M in debt. The debt funding came from Silicon Valley Bank. Twist Bioscienec is led by Emily Leproust.
posted on Tuesday, January 19, 2016 (Link to more information)
Related companies:
Twist Bioscience Corp
Related stories:
> Twist Bioscience Gains $50M More
> Twist Bioscience Raises $33 Million More
> Twist Bioscience Buys Genome Compiler
> Twist Bioscience Gets $37M
> Twist Bioscience Adds $27M
silicontap.com Home